Option Care Health, Inc. (OPCH)

盈利方式

Revenue comes from contracts with third-party payers — managed care organisations, insurers, self-insured employers, pharmacy benefit managers, Medicare and Medicaid — rather than from patients directly. The medicine itself is normally reimbursed as a discount to Average Wholesale Price or a premium to Average Sales Price, while nursing visits, compounding, delivery and ancillary supplies are billed separately or bundled into a per-diem rate. In the year to 31 December 2025, 88% of revenue came from MCOs and other non-governmental payers (including Medicare Advantage and managed Medicaid plans, PBMs and self-pay patients) and about 12% was reimbursable directly through government programmes such as Medicare and Medicaid. Economically the model is close to a spread business: the company buys the drug, is reimbursed on a formula tied to a published benchmark, and earns the difference plus the service fees — so both drug acquisition cost and payer rate changes land straight on the margin.

The company reports a single operating segment and rests its competitive case on the reputation for service quality, the strength of its national footprint and the ability to market at national, regional and local level. The practical advantage is scale in a fragmented business: 196 licensed sites in 43 states, 87 compounding pharmacies and thousands of clinicians are what let a national payer contract for coverage everywhere at once, and rebuilding that network is slow and capital-hungry. What keeps it narrow is the company's own description of its market as large and highly fragmented, with competition from vertically integrated rivals — Optum Infusion Pharmacy, Coram/CVS, Amerita, KabaFusion, Soleo Health — some of which the filing acknowledges have substantially more resources, and which own the payer or the pharmacy benefit rather than selling to it. Pricing is set by benchmark formulas and payer negotiation, not by the company.

Demand follows illness, not the economy. Volumes come from patients discharged on anti-infectives or parenteral nutrition and from chronic patients on immunoglobulin, biologics or clotting factor — treatments that are prescribed because a disease requires them and are not deferred when confidence weakens. Payers also have a structural reason to keep sending patients home: infusion outside the hospital is the cheaper site of care. The variables that actually move the results are therefore not consumer ones but the reimbursement rate, the drug mix (the filing flags accelerated adoption of lower-margin drugs as a risk), the cost of acquiring the medicine and the availability of nurses. What behaves cyclically is the margin, not the volume.

主要风险

• Reimbursement rate cuts and payer pricing pressure — The filing flags ongoing reimbursement rate reductions and pricing pressure from third-party payers, alongside federal actions and legislation that could cut rates from governmental payers. It gives one concrete example: in August 2024 CMS announced the first round of Medicare drug price negotiation results, which included a 66% reduction from the 2023 list price for one therapy in the company's portfolio, effective January 2026.
• Loss of a managed care payer relationship — The company warns that losing relationships with MCOs and other non-governmental third-party payers would cut the number of patients it can serve. These payers accounted for 88% of 2025 revenue, and the largest single payer for about 14%, so a contract lost at renewal removes patient flow the company cannot replace on its own initiative.
• Dependence on pharmaceutical manufacturers and on the drug mix — Risk factors cover changes in the pharmaceutical industry and in relationships with manufacturers — including the possibility that makers sell directly, stop supporting existing drugs, or launch products that do not need infusion — as well as the introduction of new drugs and the accelerated adoption of existing lower-margin drugs. The business only exists where a therapy has to be infused and the company can buy it.
• Concentrated drug and supply purchasing — The company discloses that disruption in pharmaceutical and medical supply could adversely affect the business, and that for the year ended 31 December 2025 approximately 68% of its pharmaceutical and medical supply purchases came from four vendors. A shortage, a recall or a contract dispute at one of those four touches a large share of what the company dispenses.
• Shortage of nurses, pharmacists and other clinical staff — A dedicated risk factor covers the shortage of qualified registered nursing staff, pharmacists and other professionals. Every infusion the company bills requires licensed hands in a patient's home or in one of its suites, so wage inflation and vacancy rates feed directly into cost of service and into how many patients can be taken on.
• Competition from vertically integrated providers — The filing cites increasing competition from established and vertically integrated healthcare providers, and names rivals including Optum Infusion Pharmacy, Coram CVS, Amerita Specialty Pharmacy, KabaFusion and Soleo Health, some with substantially more resources. It also flags dependence on maintaining relationships with patient referral sources — hospitals and physicians — which competitors owned by payers can approach from a different position.
• Regulatory compliance, audits and compounding rules — Risk factors include significant change in or non-compliance with government regulation, periodic reviews and billing audits by public and private payers, failure of a pharmacy to meet Medicare conditions of participation, and regulatory changes, increased scrutiny or reclassification of the company's compounding practices. The company also warns that delays in reimbursement may hurt liquidity and cash flow.
• Existing indebtedness and goodwill impairment — The company states that its existing indebtedness could adversely affect its business and growth prospects, and separately that changes in future business conditions could cause business investments or recorded goodwill to become impaired — a balance sheet largely built through mergers and acquisitions carries that exposure.

主要客户占营收的14%

The paying customer is the insurer, not the patient. For the year ended 31 December 2025 the largest payer represented approximately 14% of revenue and no other single payer represented more than 10%; 88% of revenue came from MCOs and other non-governmental payers and about 12% from direct government programmes. The payer base is therefore reasonably spread, but the same filing shows concentration on the supply side: roughly 68% of pharmaceutical and medical supply purchases came from four vendors.